Summary
Summary Donor-specific transplantation tolerance is an important goal for improving the quality of life of transplant patients, as it eliminates side-effects from chronic immunosuppression. Transient regimens that use a blocking CD154 antibody have been shown to promote donor-specific transplantation tolerance in mice and non-human primates. Although initial clinical trials testing CD154 had been halted due to thromboembolic complications in humans, new humanized Fc-mutated antibodies avoid FcR cross-linking and platelet aggregation and are safe. Three such antibodies are in clinical trial